Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ)
JAZZ trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/0001232524-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | JAZZ on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Ireland |
| IPO year | 2007 |
| SEC CIK | 0001232524 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Ireland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.3B |
| Net income | -$356.1M |
| Operating income | -$430.2M |
| Net margin | -8.3% |
| Operating margin | -10.1% |
| Revenue growth | +4.9% |
| Cash | $1.4B |
| Total assets | $11.7B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $2.0B cash; operating cash flow $423.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 64,189,052 (2026-10-26); 60,765,116 a year earlier; 62,956,913 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG, Dublin, Ireland | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $68.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.2B | -$483.4M | $506.1M | $2.0B | $5.6B | $4.7B | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $1.2B | $192.8M | $415.7M | $1.6B | $4.4B | $4.6B | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $1.1B | $293.1M | $408.2M | $1.8B | $5.4B | $4.4B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $1.2B | $203.5M | $362.5M | $1.4B | $5.4B | $4.3B | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $1.1B | $251.4M | $474.7M | $1.3B | $5.4B | $4.2B | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $1.0B | -$718.5M | $88.8M | $1.2B | $5.4B | $4.1B | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $897.8M | -$92.5M | $429.8M | $1.9B | $5.4B | $4.1B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $1.1B | $191.1M | $398.6M | $2.4B | $6.1B | $4.1B | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K/A | 2026-04-24 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-07-14 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.9% |
| 1 month | +14.8% |
| 3 months | -1.7% |
| Year to date | +42.1% |
| 1 year | +70.5% |
| From 52-week high | -7.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. | $77.36 | -1.20% | $15.1B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
| ELAN | Elanco Animal Health Incorporated | $26.41 | -1.38% | $13.2B |
| RDY | Dr. Reddy's Laboratories Ltd | $14.70 | -0.27% | $12.3B |
| BMRN | BioMarin Pharmaceutical Inc. | $57.99 | +1.33% | $11.2B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier